Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01619085 · ClinicalTrials.gov registry record · Phase 3
Extension Trial of the Long Term Safety of BIBF 1120 in Patients With Idiopathic Pulmonary Fibrosis
A Phase 3 study, sponsored by Boehringer Ingelheim.
- Completed
- Registry status
- Phase 3
- Development phase
- 752
- Enrollment target
NCT01619085 is a Phase 3 study that has completed, run by Boehringer Ingelheim. The registered enrollment target is 752 participants.
The verdict
NCT01619085, a Phase 3 study, has completed, sponsored by Boehringer Ingelheim.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 752 participants
- Enrollment target
Study Summary
The aim of this extension trial is to assess the long-term safety of BIBF 1120 treatment in patients with Idiopathic Pulmonary Fibrosis who have completed one year treatment and the follow up period in the double-blind phase III placebo controlled parent trials (1199.32 and 1199.34), who wish to continue treatment with BIBF 1120.
Interventions
- DRUG Nintedanib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 752 participants |
| Start Date | 2012-06-06 |
| Est. Completion | 2021-02-01 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01619085
The ClinicalTrials.gov registry entry for NCT01619085 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 752 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Boehringer Ingelheim, which has 515 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Nintedanib is the first listed.
NCT01619085 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01619085 about?
NCT01619085 is a clinical study titled "Extension Trial of the Long Term Safety of BIBF 1120 in Patients With Idiopathic Pulmonary Fibrosis". The aim of this extension trial is to assess the long-term safety of BIBF 1120 treatment in patients with Idiopathic Pulmonary Fibrosis who have completed one year treatment and the follow up period in the double-blind phase III placebo controlled parent trials (1199.32 and 1199.34), who wish to con...
What is the current status of trial NCT01619085?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 752 participants. The study started on 2012-06-06. Estimated completion is 2021-02-01.
What interventions are being tested in trial NCT01619085?
The interventions under investigation include: Nintedanib (DRUG).
Who is sponsoring clinical trial NCT01619085?
This trial is sponsored by Boehringer Ingelheim, which has 515 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.